Hormonal
In rodents, resistin is an adipokine that directly causes insulin resistance and impairs glucose tolerance, whereas in humans, resistin is primarily secreted by macrophages and serves as a marker of inflammation rather than a direct cause of insulin resistance.
While resistin levels are elevated in obesity and correlate with insulin resistance, human biology differs from rodents. In humans, resistin is largely a marker of inflammation (from macrophages) rather than a direct driver of insulin resistance from fat cells. Managing inflammation and metabolic health requires a holistic approach, not just targeting this single biomarker.
Resistin was first discovered as an adipose-secreted hormone (adipokine) linked to obesity and insulin resistance in rodents... However, in contrast to rodents, resistin is expressed and secreted from macrophages in humans and is increased in inflammatory conditions.
Why this rating
The paper is a comprehensive review citing numerous animal studies and human clinical/epidemiological studies, though human causal data is less definitive than rodent data.
Source
Resistin in Rodents and Humans
Hyeong Kyu Park et al. · Diabetes & Metabolism Journal · 2013
DOI 10.4093/dmj.2013.37.6.404
More from this paper
- In rodents, resistin administration impairs glucose tolerance and insulin action, while resistin deletion improves insulin sensitivity and glucose homeostasis.Strong
- Elevated resistin levels are predictive of atherosclerosis, coronary artery disease (CAD), and adverse cardiovascular outcomes in humans, independent of traditional risk factors like CRP.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →